首页> 外文期刊>Nature reviews. Urology >Cancer metabolomic markers in urine: evidence, techniques and recommendations
【24h】

Cancer metabolomic markers in urine: evidence, techniques and recommendations

机译:尿液中的癌症代谢组分:证据,技术和建议

获取原文
获取原文并翻译 | 示例
       

摘要

Urinary tests have been used as noninvasive, cost-effective tools for screening, diagnosis and monitoring of diseases since ancient times. As we progress through the 21st century, modern analytical platforms have enabled effective measurement of metabolites, with promising results for both a deeper understanding of cancer pathophysiology and, ultimately, clinical translation. The first study to measure metabolomic urinary cancer biomarkers using NMR and mass spectrometry (MS) was published in 2006 and, since then, these techniques have been used to detect cancers of the urological system (kidney, prostate and bladder) and nonurological tumours including those of the breast, ovary, lung, liver, gastrointestinal tract, pancreas, bone and blood. This growing field warrants an assessment of the current status of research developments and recommendations to help systematize future research.
机译:尿检已被用作自古以来的筛选,诊断和监测疾病的非侵入性,具有成本效益的工具。 随着我们通过21世纪的进展,现代分析平台已经启用了代谢物的有效测量,具有更深入了解癌症病理生理学的有希望的结果,并最终临床翻译。 第一次使用NMR和质谱(MS)测量代原尿癌生物标志物(MS)的研究于2006年公布,从那时起,这些技术已被用于检测泌尿外系统(肾,前列腺和膀胱)的癌症和包括那些 乳房,卵巢,肺,肝,胃肠道,胰腺,骨骼和血液。 这种不断增长的现场保证评估目前的研究发展和建议,以帮助系统化未来的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号